These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 2092106)

  • 21. A comparative analysis of the serum levels of NCC-ST-439, CEA and CA19-9 in patients with colorectal carcinoma.
    Iemura K; Moriya Y
    Eur J Surg Oncol; 1993 Oct; 19(5):439-42. PubMed ID: 8405479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
    Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
    Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Determination of the tumor marker CA 72-4 in gastric carcinoma].
    Martín-Pérez E; Fernández-Arjona M; Baza B; Villanueva C; Larrañaga E; Serrano PA; Clerigué A
    Rev Esp Enferm Dig; 1993 Feb; 83(2):92-6. PubMed ID: 8471361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical significance of plasma fibrinogen level in patients with colorectal cancer].
    Wang Q; Xie R; Zhang QY
    Zhonghua Zhong Liu Za Zhi; 2005 Sep; 27(9):544-6. PubMed ID: 16438853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease.
    Engarås B; Kewenter J; Nilsson O; Wedel H; Hafström L
    Eur J Surg Oncol; 2001 Feb; 27(1):43-8. PubMed ID: 11237491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
    Chen C; Chen LQ; Yang GL; Li Y
    Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Limited clinical significance of the serum tumour marker Ca 72-4 in colorectal cancer.
    Lindmark G; Kressner U; Bergström R; Glimelius B
    Anticancer Res; 1996; 16(2):895-8. PubMed ID: 8687147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carbohydrate antigen expression in colorectal cancer.
    Kim YS
    Semin Cancer Biol; 1990 Jun; 1(3):189-97. PubMed ID: 2103494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical evaluation of a combination assay of CEA, CA-19-9 and TPA in patients with colorectal cancer].
    Nishida O; Shiroto H; Satoh N; Nakajima Y; Manabe K; Kondoh Y; Sano F; Uchino J
    Gan No Rinsho; 1988 Aug; 34(9):1096-100. PubMed ID: 3172515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor markers in staging and prognosis of colorectal carcinoma.
    Levy M; Visokai V; Lipska L; Topolcan O
    Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The concentration of carcinoembryonic antigen and carbohydrate antigen Ca-19-9 in the blood serum in cancerous diseases of the gastrointestinal tract].
    Mit'kov VV; Ogneva TV; Goriaĭnova II; Milanov S; Milkov V
    Med Radiol (Mosk); 1989 Nov; 34(11):22-4. PubMed ID: 2586258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of the major sialyl-Lex-positive mucins present in colon, colon carcinoma, and sera of patients with colorectal cancer.
    Hanski C; Hanski ML; Zimmer T; Ogorek D; Devine P; Riecken EO
    Cancer Res; 1995 Feb; 55(4):928-33. PubMed ID: 7850810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diagnostic value of serum CA 19-9 determination in digestive tract cancer].
    Chen SB
    Zhonghua Zhong Liu Za Zhi; 1990 Jan; 12(1):58-60. PubMed ID: 2364873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in prognosis of colorectal cancer patients based on the expression of sialyl Lewisa, sialyl Lewisx and sialyl Tn antigens in serum and tumor tissue.
    Akamine S; Nakagoe T; Sawai T; Tsuji T; Tanaka K; Hidaka S; Shibasaki S; Nanashima A; Yamaguchi H; Nagayasu T; Yasutake T
    Anticancer Res; 2004; 24(4):2541-6. PubMed ID: 15330211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Serum markers in breast cancer and colorectal cancer (1997)].
    Bellet D; Mlika-Cabanne N; Bedenne L; Brun B; Demeaux JL; Legrand JL; Lorimier G; Mignotte H; Ollivier JM; Piperno-Neumann S; Rinaldi Y; Rousset H; Rymer JC; Laversin S
    Gynecol Obstet Fertil; 2001 Jan; 29(1):62-3. PubMed ID: 11217195
    [No Abstract]   [Full Text] [Related]  

  • 36. [Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer].
    Grotowski M
    Pol Merkur Lekarski; 2002 Jan; 12(67):77-80. PubMed ID: 11957811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experience with CA 15.3 as a tumor marker in breast cancer.
    Barros AC; Fry W; Nazario AC; Santos MO; Sato MK
    Eur J Surg Oncol; 1994 Apr; 20(2):130-3. PubMed ID: 8181577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum tumor markers.
    Perkins GL; Slater ED; Sanders GK; Prichard JG
    Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of circulating sialyl Tn antigen in colorectal cancer patients.
    Nakagoe T; Sawai T; Tsuji T; Jibiki M; Nanashima A; Yamaguchi H; Kurosaki N; Yasutake T; Ayabe H; Tagawa Y
    Anticancer Res; 2000; 20(5C):3863-9. PubMed ID: 11268468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
    Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
    Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.